© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
June 11, 2014
Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association
May 29, 2014
The recent approval of several new agents for the treatment of prostate cancer has heralded a new era for managing this condition.
May 16, 2014
More recently, researchers seek to understand the mechanisms related to tumor dissemination in hopes of therapeutically targeting this process.
April 25, 2014
The treatment decisions for NSCLC are primarily dependent on the patient's performance status, extent of disease, and histological subtype. Significant developments in the area of targeted therapies have changed the treatment paradigm for NSCLC.